Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Non-Current Deffered Revenue (2022 - 2024)

Historic Non-Current Deffered Revenue for Century Therapeutics (IPSC) over the last 3 years, with Q3 2024 value amounting to $109.8 million.

  • Century Therapeutics' Non-Current Deffered Revenue fell 212.39% to $109.8 million in Q3 2024 from the same period last year, while for Sep 2024 it was $109.8 million, marking a year-over-year decrease of 212.39%. This contributed to the annual value of $111.4 million for FY2023, which is 49.35% up from last year.
  • Latest data reveals that Century Therapeutics reported Non-Current Deffered Revenue of $109.8 million as of Q3 2024, which was down 212.39% from $109.8 million recorded in Q2 2024.
  • Century Therapeutics' Non-Current Deffered Revenue's 5-year high stood at $115.8 million during Q1 2022, with a 5-year trough of $109.2 million in Q2 2023.
  • Over the past 3 years, Century Therapeutics' median Non-Current Deffered Revenue value was $110.8 million (recorded in 2022), while the average stood at $111.2 million.
  • Over the last 5 years, Century Therapeutics' Non-Current Deffered Revenue had its largest YoY gain of 109.25% in 2023, and its largest YoY loss of 516.8% in 2023.
  • Century Therapeutics' Non-Current Deffered Revenue (Quarter) stood at $110.8 million in 2022, then grew by 0.49% to $111.4 million in 2023, then decreased by 1.45% to $109.8 million in 2024.
  • Its Non-Current Deffered Revenue stands at $109.8 million for Q3 2024, versus $109.8 million for Q2 2024 and $110.3 million for Q1 2024.